Eben@CANSLIM ResearchSOLS reported earnings per share of $0.80, which exceeded the consensus estimate of $0.69 by 15.21%, accompanied by revenue growth of 11.13% year-on-year.
The current share price of $61.74 sits above the 50-day moving average of $59.90 but below the 200-day moving average of $70.19, and is 30.32% below its 52-week high; this configuration meets three out of seven criteria in the Canslim score.
This summary reflects only the reported figures: a positive EPS surprise, revenue expansion, and price positioning relative to technical averages within a declining trend stage.
Rule-Based Scorecard (Factual Screen)
| Key Metric | Reported / Current | Benchmark / Consensus | Status |
|---|---|---|---|
| Quarterly EPS (C) | $0.8 (N/A) | $0.69 (Surprise: +15.2%) | Fail |
| Quarterly Revenue | $1.15B (+11.1% YoY) | Year-on-year change | Pass |
| Annual EPS Growth (A) | +-31%/yr | ≥25% Annual CAGR | Fail |
| 52-Week High Range (N) | -30.3% off high | Within 15% of High | Fail |
| Relative Strength (L) | +29.0% vs SPY | Ahead of SPY over 12 months | Pass |
| Institutional Float (I) | 86% | 30% – 90% Float Ownership | Pass |
| Trend Template (Minervini-style) | 3 / 7 Criteria | Trend-template criteria met | Stage 4 (Declining) |
| CANSLIM-style Rule Score | 3 / 7 Criteria | Rule threshold (factual screen) | 3 of 7 rule criteria met (factual screen, not a rating) |
Stage, pattern and sentiment labels are generated by rule-based approximations (Weinstein stage analysis, Minervini trend template and heuristic pattern detection), not by precise technical analysis. Data as of November 05, 2026. For informational and educational purposes only — not investment advice. Always verify against primary sources before making any investment decision.
How this report was made: generated automatically by the Eben (AI) pipeline from Yahoo Finance data. Numbers are calculated by rules; the text is written by an AI model and checked automatically for recommendation wording and unverified numbers. It may still contain errors — verify against the company’s filings.
Disclosure: the publisher of CANSLIM Research does not hold a position in SOLS at the time of publication.
None of CANSLIM Research’s hypothetical model paper portfolios holds the securities named here at the time of publication.
Trading policy: the publisher does not buy or sell a security in the two US trading days before or after CANSLIM Research publishes it by name.
This is a factual, rule-based screen of SOLS. For education and research only. This is general information, the same for every reader; it does not consider anyone’s objectives or circumstances and is not investment advice, an offer, or a recommendation to buy, sell or hold any security. CANSLIM Research is not licensed or registered with any securities regulator in any jurisdiction and does not advise on whether, which or when to buy or sell any security. Investing involves risk, including the loss of capital.
CAN SLIM® is a registered trademark of Investor’s Business Daily, Inc.; CANSLIM Research is independent and not affiliated with or endorsed by it or by any trader whose published method is referenced.
Prepared by Eben (AI) — an automated research pipeline. Factual screen for education and research; not investment advice.